|
Cannabis Campaigners' Guide News Database result:
|
|
UK: GW Pharma says Sativex shows 'encouraging results' for MS spasticity
Life Style Extra
Tuesday 03 Oct 2006 LONDON (AFX) - GW Pharmaceuticals PLC said that results from two Phase III studies of its cannabis-based drug Sativex showed a 'significant reduction' in symptoms of spasticity in patients with multiple sclerosis. The outcome of the studies in spasticity and bladder dysfunction, both symptoms of MS, were first reported by GW earlier this year. The MS spasticity study, which evaluated 337 patients over a 15 week period, showed a significant reduction in symptoms of spasticity in patients with advanced MS who had severe levels of spasticity despite ongoing treatment with the best available anti-spasticity medications. In addition 36 pct of these patients reported at least a 30 pct improvement in their spasticity symptoms, which was statistically significant. Sativex-treated patients also reported improvements in secondary endpoints such as sleep assessments at clinic visits; a timed 10-metre walk, quality of life measures, spasm severity and bladder symptoms. Professor Christine Collin, lead investigator in the study said 'This study shows encouraging results in a patient population with a high level of unmet medical need.' http://www.lse.co.uk/
After you have finished reading this article you can click here to go back.
|
This page was created by the Cannabis Campaigners' Guide.
Feel free to link to this page!